Skip to main content
Aptamer Sciences Inc logo

Aptamer Sciences Inc — Investor Relations & Filings

Ticker · 291650 ISIN · KR7291650000 KO Manufacturing
Open in API
Filings indexed 230 across all filing types
Latest filing 2021-03-17 Audit Report / Informat…
Country KR South Korea
Listing KO 291650

About Aptamer Sciences Inc

https://aptsci.com/en/

Aptamer Sciences Inc. is a clinical-stage biopharmaceutical company specializing in aptamer technology. The company has established a proprietary, integrated platform for the discovery and development of aptamer-based therapeutics and diagnostics. Its primary focus is on oncology, utilizing its Aptamer-Drug Conjugate (ApDC™) platform to create targeted cancer treatments. The lead candidate, AST-201, is an ApDC targeting the GPC3 protein, which is highly expressed in solid tumors such as liver cancer. The company is advancing AST-201 through clinical trials to evaluate its safety and efficacy. The development pipeline also includes other innovative platforms like Aptamer Radioligand Conjugates (ApRC) and Aptamer Immune Stimulator Conjugates (ApIS), aimed at addressing unmet medical needs in hemato-oncology and other areas. Aptamer Sciences leverages its technology to develop novel therapies with the potential for high specificity and efficacy.

Recent filings

Filing Released Lang Actions
감사보고서제출
Audit Report / Information Classification · 1% confidence The document is a formal filing titled 'Audit Report Submission' (감사보고서 제출) from Aptamer Sciences. It provides the audit opinion (unqualified/proper), key financial data, and details regarding the auditor (Samil PwC). While it contains financial data, it is a summary disclosure of the audit results rather than the full Annual Report (10-K) or a standalone audit report document. Under the provided definitions, this fits the 'Audit Report / Information' (AR) category as it specifically reports on the audit opinion and financial results as audited by the accounting firm. FY 2020
2021-03-17 Korean
사업보고서 (2020.12)
Audit Report / Information Classification · 1% confidence The document is a formal 'Audit Report' (감사보고서) for the company 'Aptamer Sciences' (주식회사 압타머사이언스) for the fiscal year ending December 31, 2020. It includes the independent auditor's report from Samil PricewaterhouseCoopers, the audit opinion, key audit matters, and the full set of financial statements (Balance Sheet, Income Statement, Statement of Changes in Equity, Cash Flow Statement, and Notes). This is a comprehensive financial document, not an announcement or a summary, and fits the definition of an Audit Report/Information (AR). FY 2020
2021-03-17 Korean
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a 'Notice of General Meeting of Shareholders' (주주총회소집공고) for Aptamer Science. It contains the agenda for the meeting, including the approval of financial statements, election of directors, and amendments to the articles of incorporation. This type of document is a formal proxy statement/information circular provided to shareholders to solicit votes and inform them of meeting details, which falls under the Proxy Solicitation & Information Statement category.
2021-03-10 Korean
[기재정정]주주총회소집결의
AGM Information Classification · 1% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) issued by Aptamer Sciences. It details the agenda items, including the approval of financial statements, election of directors and auditors, and remuneration limits. This document serves as a proxy solicitation and information statement provided to shareholders to inform them of the meeting's purpose and to request their votes. It fits the definition of Proxy Solicitation & Information Statement (PSI).
2021-02-24 Korean
주주총회소집결의
AGM Information Classification · 1% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) issued by Aptamer Sciences. It outlines the date, location, and agenda items for the upcoming Annual General Meeting, including the approval of financial statements, amendments to the articles of incorporation, and the appointment of directors and auditors. This type of document is a standard proxy solicitation and information statement provided to shareholders to inform them of meeting details and request their participation/votes.
2021-02-23 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Earnings Release Classification · 1% confidence The document is a regulatory filing from Aptamer Science regarding a significant change (greater than 30%) in revenue or profit structure. This is a standard disclosure requirement in the Korean market (DART system) for listed companies to announce preliminary financial results or significant fluctuations before the final audit report is finalized. Since it provides key financial highlights and reasons for the change, it falls under the Earnings Release (ER) category. FY 2020
2021-02-08 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.